Synovo
A stranger
EvaMobs: Evolvable and rapidly adaptable monobodies: a broad-spectrum antiviral platform
SYNOVO GMBH
participó en un
HORIZON EUROPE
HORIZON-HLTH-2023-DISEASE-03
With progress in globalization, expansion of human populations into natural habitats, and aggravation of climate change comes an increased r...
2023-11-23 - 2028-12-31 | financed
2023-11-23 - 2028-12-31 | financed
Algae4IBD: ALGAE4IBD FROM NATURE TO BEDSIDE ALGAE BASED BIO COMPOUND FOR PREVENTION AND TREATMENT OF INFLAMMA...
SYNOVO GMBH
participó en un
H2020
H2020-FNR-2020
Algae4IBD's mission is to develop commercial products for Inflammatory Bowel Disease (IBD) prevention and treatment using aquatic natural bi...
2021-05-03 - 2025-05-31 | financed
2021-05-03 - 2025-05-31 | financed
NOVIRUSES2BRAIN: One size fits all unique drug to eradicate multiple viral species simultaneously from the centra...
SYNOVO GMBH
participó en un
H2020
H2020-FETOPEN-2018-2020
Viruses that infect the brain and other parts of the central nervous system are a worldwide threat of terrible dimensions. Viruses such as Z...
2018-12-17 - 2025-08-31 | financed
2018-12-17 - 2025-08-31 | financed
FOLSMART: Folate Target Nanodevices To Activated Macrophages For Rheumatoid Arthritis
SYNOVO GMBH
participó en un
H2020
H2020-NMP-2014-2015
FOLSMART will bring to phase I clinical trials novel folate-based nanodevices (FBN) for the treatment of rheumatoid arthritis (RA). These na...
2015-11-25 - 2020-12-31 | financed
2015-11-25 - 2020-12-31 | financed
KINACEPT: Novel anti inflammatory compounds for autoimmune diseases
SYNOVO GMBH
processed a
FP7
The consortium has a lead series of p38 inhibitors with unusual anti-inflammatory properties. The drug leads were originally elaborated...
financed
financed
InFact: Functional materials for fast diagnosis of wound infection
SYNOVO GMBH
participó en un
FP7
"Early detection of an incipient wound infection is a challenge for the attending physician , since its early diagnosis allows the timely i...
financed
financed
NOVO: Novel approaches for prevention and degeneration of pathogenic bacteria biofilms formed on medical d...
SYNOVO GMBH
participó en un
FP7
Biofilms are bacterial communities encased in a self-produced hydrated polymeric matrix. An important characteristic of microbial biofilms i...
financed
financed
PEP2BRAIN: Selected peptides as drug candidates directed to pain and neurodegeneration
SYNOVO GMBH
participó en un
FP7
"BLV200703/4 is a small molecule discovered jointly by groups from the University of Lisbon (Portugal) and Girona (Spain) that proved its ef...
financed
financed
TIMCC: Tumor Infiltrating Myeloid Cell Compartment
SYNOVO GMBH
participó en un
FP7
The ITN TIMCC brings together eight expert teams from different disciplines within Immunology, Genetics and Oncology, to provide substantive...
financed
financed
VISION: Prolonged inhibition of semaphorine3a pathway via a bio degradable implant towards a better therapy...
SYNOVO GMBH
participó en un
FP7
The visual pathway is a component of the central nervous system (CNS) and therefore is not regenerative. Acute optic nerve injury, ischemic...
financed
financed
NANOFOL: Folate based nanobiodevices for integrated diagnosis therapy targeting chronic inflammatory diseases
SYNOVO GMBH
participó en un
FP7
NANOFOL proposes to develop a new diagnostic/therapy approach using folate based nanobiodevices (FBN) able to provide a new type of cost eff...
financed
financed
* No data from the current company are not available.